This intellectual property protects Kiora's pipeline by covering multiple small molecule analogs, delivery methods, and several inflammatory-related therapeutic applications, including posterior non-infectious uveitis, extending market exclusivity for approved indications in the United States and Europe.
Read More
Study: Scientists develop new therapeutic model for potentially treating incurable eye diseases
August 24th 2023A team of researchers have successfully transplanted human microglia into a mouse retina to create a model for studying eye disease treatments, such as diabetic retinopathy, glaucoma and age-related macular degeneration.
Read More
Study: Few children – especially those with safety-net insurance – get vision checked at checkups
August 24th 2023According to researchers from University of Michigan and Duke University, children with Medicaid or other public insurance are far less likely than those with private insurance to have had a vision check in the last year at a primary care office.
Read More
Cochrane Review: Blue-light filtering glasses show inconclusive outcomes
August 23rd 2023Clinicians' expertise can help assess inconclusive findings about the benefits of blue-light filtering glasses. This enables them to offer informed guidance to patients concerned about eye strain and sleep quality.
Read More
FDA approves aflibercept injection 8mg for treatment of wet AMD, DME, DR
August 19th 2023According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.
Read More
ASRS 2023: Insights on AVD-104, a sialic-acid coated nanoparticle therapeutic for geographic atrophy
August 15th 2023Carl Regillo, MD, FACS, FASRS, spoke with our team following the annual ASRS meeting in Seattle, Washington to share insights from his presentation titled, "Modulation of Macrophages and Complement Dysfunction in Non-exudative AMD utilizing novel, sialic-acid coated nanoparticles." Aviceda Therapeutics is unlocking the proteogenomic code of AMD to target proteins and pathways linked to macular degeneration.
Read More
What causes spontaneous eye movements in albinism?
August 15th 2023A team of researchers from the Netherlands Institute for Neuroscience, one of the causes is the spontaneous back-and-forth movement of the eye is pendular nystagmus. The researchers have demonstrated that the nucleus of the optic tract might be the source of the problem.
Read More